Virtu Financial Reports Q3 2025 Earnings with Revenue Growth and Product Pipeline Highlights

Virtu Financial (VIRT) reported Q3 2025 earnings with 6% constant currency revenue growth, driven by its base business and innovative products. The company highlighted strong performance in pharmaceuticals, with $84 million in Miebo revenue, and 27% growth in premium intraocular lenses. The CEO emphasized the company's pipeline of clinical-stage products set for future launches.

By Motley Fool Transcribing, The Motley Fool Tue, April 21, 2026 at 6:57 PM GMT+3 44 min read · Yahoo Finance · April 21, 2026, 15:57 UTC

Tickers: $VIRT

Topics: earnings financial performance M&A pharmaceuticals product launches revenue growth

Read the full article at Yahoo Finance

More World news

Nvidia Names Colette Kress Interim CEO Following Jensen Huang's Resignation Motley Fool · November 12, 2026, 18:26 UTC
Bit Digital Reports Q3 2026 Net Income of $28.5 Million Amid Revenue Decline Motley Fool · November 12, 2026, 18:26 UTC
EZCORP Reports Strong Q4 2026 Results with Significant EBITDA and Revenue Growth Motley Fool · November 12, 2026, 18:16 UTC
Sabre Corp Shares Decline Following Travelport Denial of Merger Speculation Seeking Alpha · November 12, 2026, 18:21 UTC
Lufax Reports Third Quarter 2026 Net Loss Amid Rising Credit Impairment Costs Motley Fool · November 12, 2026, 18:15 UTC
Avantor Reports Return to Organic Revenue Growth in Third Quarter 2026 Motley Fool · November 12, 2026, 18:15 UTC
MGP Ingredients Rebrands to Sempreon and Announces Strategic Shift Toward Ready-to-Drink Products Motley Fool · November 12, 2026, 18:15 UTC
ICON Reports Q3 2026 Revenue of $2 Billion and Accelerating Book-to-Bill Ratio Motley Fool · November 12, 2026, 18:15 UTC
Beachbody (BODi) Reduces Annual Revenue Breakeven to $125 Million Amid Strategic Pivot Motley Fool · November 12, 2026, 18:15 UTC
Standard Nuclear Reports $577.2 Million Contract Backlog and Targets 2027 DOE Authorization Seeking Alpha · November 12, 2026, 18:10 UTC